Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biovail facing grand jury investigation

Executive Summary

The Massachusetts Attorney General's office is pursuing a grand jury investigation of Biovail's 2003 launch of Cardizem LA (diltiazem), particularly its program to encourage doctors to prescribe the long-acting formulation of the antihypertensive drug. Under this program, physicians who prescribed the drug to up to 15 patients and completed a questionnaire were entitled to receive $1,000. In launching Cardizem, Biovail said it would be aggressive in seeking to convert users of other diltiazem products, including its own Cardizem CD, to Cardizem LA (1"The Pink Sheet" Feb. 10, 2003, p. 27). The AG's office began an administrative inquiry into the program in 2003, and at that time the HHS Office of Inspector General launched a similar investigation...

You may also be interested in...

Biovail Cardizem LA Bedtime/Morning Dosing Flexibility Included In Label

Biovail will launch Cardizem LA on April 2 following FDA's Feb. 6 approval of the "graded-release," once-daily diltiazem for hypertension

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts